India Medical Device Market Entry Roadmap: From MD-14 to MD-15

1. Key takeaways

From zero to lawful sale in India, the standard route consists of seven steps: classification determination → route selection → appointment of the Authorised Indian Agent → assembly of the technical documentation → filing of the MD-14 with fee payment → responding to queries and a possible overseas site inspection → obtaining the MD-15 and completing customs clearance. The statutory approval timeline is 9 months from the date of application (Rule 36(1)); the actual duration depends on the quality of the dossier and the number of query rounds. Treating the seven steps as a single undifferentiated queue is the main reason projects stall: the early steps determine which regulatory machinery applies, and the late steps only run as fast as the early ones were run correctly.

• Seven steps run from classification to clearance and MD-15.
• The statutory review clock is 9 months under Rule 36(1).
• Actual duration depends on dossier quality and query rounds.
• Route selection is the most expensive decision point in the sequence.
• Overseas site inspection is a cost and schedule variable the applicant partly controls.

2. Legal basis

Each step of the roadmap rests on identifiable provisions and official interpretations, which makes the route auditable: for every step, the governing source and the operative point can be stated in advance. The table below provides that mapping. Projects that cannot fill in this table for their own product have not yet started the regulatory work, whatever else they may have produced.

3. Expert insights

Insight one: the 9 months is a statutory review period, not a delivery promise. Rule 36(1) sets the time within which the CLA must decide, and it runs regardless of whether a site inspection takes place. It does not include the time the enterprise spends preparing documents, nor the time consumed by query-and-response cycles. In planning, it should be treated as the clock of the review stage only, not as the total project duration. Companies that communicate the statutory period as their launch date systematically disappoint their commercial stakeholders and their distributors alike.

Insight two: step 2 is the most expensive decision point. This single step determines three branch lines at once: whether the product falls within the Class A exemption; whether a six-jurisdiction FSC exists (deciding whether an Indian clinical investigation is required); and whether the device is novel (deciding whether the MD-26 → MD-27 prior-permission line must be run first). Each of the three branches can move the total timeline by more than half a year, which is why the step deserves proportionate analytical effort before any document is drafted.

Insight three: the overseas site inspection is a key the applicant partly controls. The inspection fee of USD 6,000 is borne by the applicant. Whether an inspection is triggered correlates with the completeness of the dossier, the presence or absence of six-jurisdiction approvals, and the risk class of the product. It is both a cost item and a schedule item, and the applicant’s own submission quality is one of the few levers over it. A dossier that anticipates inspector questions reduces the probability that the key turns the wrong way.

4. Practical recommendations

• GRZAN divides the seven steps into two gates: gate one asks whether the project can be done (classification + route + six-jurisdiction evidence), and gate two asks how long it will take (documents + filing + queries).
• If gate one is not passed, the project does not enter gate two — no drafting effort is spent on a route that cannot carry the product.
• Schedules given to clients are computed as document preparation of 2–4 months + the statutory 9-month review period after filing + a query buffer, never as a flat 9-months-to-certificate figure.
• Every step’s output is a written artefact — the classification conclusion, the route decision, the agent appointment, the document set, the fee computation, the query responses, the clearance plan — so that progress is auditable rather than anecdotal.
• Step 2 conclusions are re-confirmed whenever the classification list or the recognised-jurisdiction status changes during the project.

5. Verification checklist

• □ Step 1: the classification conclusion has been documented.
• □ Step 2: the route (exemption registration / regular MD-14 / novel device MD-27) has been determined.
• □ Step 3: the AIA’s licensed status is confirmed and the PoA legalised.
• □ Step 4: the DMF/PMF/FSC/ISO 13485/labels are complete and mutually consistent.
• □ Step 5: fees have been computed as the Second Schedule site fee plus per-device fee.
• □ Step 6: a query response mechanism and an overseas inspection contingency plan are in place.
• □ Step 7: wholesale registration and customs clearance arrangements have been started for the post-certificate stage.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including India. Our team prepares dossiers to CDSCO expectations, manages SUGAM submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Regulatory information verified as of 27 October 2026.